Real Time 7.25 1.26 (21.04%) 9:58AM EDT
Sell at 7.60 short term
SOUTH SAN FRANCISCO (TheStreet) -- Treatment with Exelixis'(EXEL) experimental drug cabozantinib helps patients with a form of thyroid cancer significantly extend the time before their disease worsens, according to results from a late-stage study announced Monday.
Sell at 7.60 short term
SOUTH SAN FRANCISCO (TheStreet) -- Treatment with Exelixis'(EXEL) experimental drug cabozantinib helps patients with a form of thyroid cancer significantly extend the time before their disease worsens, according to results from a late-stage study announced Monday.
